Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 241-527-8 | CAS number: 17527-29-6
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
In accordance with Regulation (EC) No 1907/2006 Annex VIII section 8.8.1, a toxicokinetics study is not required as assessment of the toxicokinetic behaviour of analogue substances has been derived from the relevant available information. This assessment is located within the endpoint summary for toxicokinetics, metabolism and distribution.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 10
- Absorption rate - inhalation (%):
- 100
Additional information
13F-SFA is expected to be mainly absorbed via the oral route, or dermal route (assumed to be 10%). Following hydrolysis by esterase, 13F-SFA is proposed to be metabolized to acrylic acid and 6-2 FTOH. The primary excretory metabolite of acrylic acid is carbon dioxide. Potential intermediate metabolites of 6-2 FTOH are 6-2 FTCA, 6-2 FTUCA, 5-3 FTUCA and 5-3 FTCA, following elimination of HF, and the terminal metabolites of 6-2 FTOH are PFHxA and PFHpA (anticipated to be minor amounts), which are considered to contribute to the observed effects of 13F-SFA. Metabolites of acrylic acid are expected to distribute into liver, blood, or forestomach, and those of 6-2 FTOH will distribute into liver, blood, kidney and other tissues investigated (spleen, gonads and brain) as well as fat. It is expected that 13F-SFA has no significant potential for bioaccumulation in the body. All metabolites of 13F-SFA and parent compound can be excreted via respiration, urine and feces.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
